KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$1.25.

  • Novavax's EPS (Basic) fell 6447.37% to -$1.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.11, marking a year-over-year increase of 19634.7%. This contributed to the annual value of -$1.23 for FY2024, which is 7722.72% up from last year.
  • Latest data reveals that Novavax reported EPS (Basic) of -$1.25 as of Q3 2025, which was down 6447.37% from $0.66 recorded in Q2 2025.
  • Novavax's EPS (Basic)'s 5-year high stood at $3.22 during Q1 2025, with a 5-year trough of -$11.31 in Q4 2021.
  • Its 5-year average for EPS (Basic) is -$1.9, with a median of -$1.26 in 2023.
  • In the last 5 years, Novavax's EPS (Basic) crashed by 148333.33% in 2021 and then soared by 40666.67% in 2025.
  • Quarter analysis of 5 years shows Novavax's EPS (Basic) stood at -$11.31 in 2021, then soared by 79.75% to -$2.29 in 2022, then rose by 22.69% to -$1.77 in 2023, then soared by 69.92% to -$0.53 in 2024, then crashed by 134.77% to -$1.25 in 2025.
  • Its EPS (Basic) stands at -$1.25 for Q3 2025, versus $0.66 for Q2 2025 and $3.22 for Q1 2025.